Company profile
TMS company profile
TMS is a Tokyo-based clinical-stage biotech company that unlocks fungus-derived SMTP small molecule compound group. SMTPs have novel dual mode of action, both thrombolytic and anti-inflammatory. The lead compound TMS-007 is in Phase IIa clinical trial indicated for acute ischemic stroke and partnered with Biogen.
Business identity
- Contact email
- [email protected]
- Phone number
- +81-42-306-5087
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 00011-00050 employees
- Revenue range
- $1K+
- Founded
- 2005-02-17
Headquarters
- Headquarters
- Fuchu, Japan, Tokyo
- Country code
- JP
- Continent
- Asia